A patient with CRC had been previously reported to receive an infusion of ex-vivo expanded T cells with HLA-C*08:02 restriction and KRAS G12D reactivity, resulting in the regression of metastatic lung lesions (57). This evidence concerns the gene KRAS and colorectal carcinoma.